List prices in drug ads on TV com­ing as CMS fi­nal­izes rule

De­spite nu­mer­ous com­ments rais­ing ques­tions about a pro­pos­al to in­clude list prices in phar­ma­ceu­ti­cal di­rect-to-con­sumer (DTC) ad­ver­tise­ments, the Cen­ters for Medicare and Med­ic­aid Ser­vices (CMS) on Wednes­day moved ahead and fi­nal­ized the pro­pos­al.

The fi­nal rule, which will take ef­fect in Ju­ly, re­quires that tele­vi­sion ad­ver­tise­ments for pre­scrip­tion drugs or bi­o­log­i­cal prod­ucts with a list price of $35 or more con­tain a state­ment in­di­cat­ing the Whole­sale Ac­qui­si­tion Cost (al­so re­ferred to as WAC or the list price) for a typ­i­cal 30-day reg­i­men or for a typ­i­cal course of treat­ment, whichev­er is most ap­pro­pri­ate.

The dis­clo­sure, which will be de­ter­mined on the first day of the quar­ter dur­ing which the ad­ver­tise­ment is be­ing aired or oth­er­wise broad­cast, will be in­clud­ed as fol­lows: “The list price for a (30-day sup­ply of ) (typ­i­cal course of treat­ment with) (name of pre­scrip­tion drug or bi­o­log­i­cal prod­uct) is (in­sert list price). If you have health in­sur­ance that cov­ers drugs, your cost may be dif­fer­ent.”

In de­fend­ing its rule, the CMS ex­plained how in 2017, over $5.5 bil­lion was spent on pre­scrip­tion drug ad­ver­tis­ing, in­clud­ing near­ly $4.2 bil­lion on tele­vi­sion ad­ver­tis­ing. And spend­ing on DTC phar­ma­ceu­ti­cal com­mer­cials in­creased 62 per­cent be­tween 2012 and 2017.

Mean­while, a re­cent poll by the Kaiser Fam­i­ly Foun­da­tion found that 88% of Amer­i­cans sup­port re­quir­ing drug man­u­fac­tur­ers to in­clude their list prices in DTC ad­ver­tise­ments, the CMS said.

Crit­ics of the pro­pos­al, how­ev­er, have ex­plained how in­clud­ing the prices in DTC ads is not like­ly to low­er drug prices over­all, how list prices are not rep­re­sen­ta­tive of what con­sumers pay, how the CMS has not cre­at­ed an en­force­ment mech­a­nism to en­sure com­pa­nies com­ply with the new rule, and some even ques­tioned whether the new re­quire­ment should fall un­der the CMS’ purview.

In de­fend­ing its right to re­quire the list price dis­clo­sures, the CMS said in the fi­nal rule: “Al­though we ac­knowl­edge that nei­ther sec­tion 1102 nor sec­tion 1871 of the So­cial Se­cu­ri­ty Act specif­i­cal­ly ref­er­ences pre­scrip­tion drugs or bi­o­log­i­cal prod­ucts, their prices, or ad­ver­tise­ments, we nev­er­the­less be­lieve that re­quir­ing man­u­fac­tur­ers to in­clude list prices in DTC tele­vi­sion ad­ver­tise­ments is sup­port­ed by the plain text of these statutes.”

In terms of the WAC not be­ing a mean­ing­ful mea­sure of what a pa­tient will pay for a drug, the CMS coun­tered with a re­cent JA­MA study that found con­sumers could more ac­cu­rate­ly de­ter­mine their out-of-pock­et costs when list prices were dis­closed.

Some crit­ics al­so con­tend­ed that the rule would be a vi­o­la­tion of man­u­fac­tur­ers’ First Amend­ment rights.

But the CMS coun­ters that “the speech here at is­sue does not im­pli­cate core First Amend­ment in­ter­ests. Man­u­fac­tur­ers al­ready dis­close the very same in­for­ma­tion at is­sue, their prod­ucts’ WACs, to pur­chasers as well as pub­lish­ers of var­i­ous pric­ing data­bas­es and oth­er com­pen­dia.”

The CMS al­so took is­sue with in­dus­try group PhRMA’s re­cent­ly im­ple­ment­ed vol­un­tary pro­gram to re­quire mem­ber com­pa­nies to dis­close drug prices on­line.

“PhRMA’s is­suance of a new guid­ing prin­ci­ple in Oc­to­ber 2018 does not change the need for the rule. The
PhRMA prin­ci­ples are vol­un­tary; they are not bind­ing on PhRMA mem­bers, let alone non-mem­bers, and there is noth­ing to pre­vent PhRMA from re­vis­ing its prin­ci­ples at any time … We be­lieve that rel­a­tive­ly few view­ers will make use of the ap­proach ad­vo­cat­ed by the PhRMA pro­pos­al, even as­sum­ing that its mem­bers im­ple­ment the pro­pos­al,” the CMS said.

PhRMA said in a state­ment Wednes­day that it be­lieves “there are op­er­a­tional chal­lenges, par­tic­u­lar­ly the 60-day im­ple­men­ta­tion time­frame, and think the fi­nal rule rais­es First Amend­ment and statu­to­ry con­cerns.”

But as far as en­force­ment of the rule, the CMS does not plan to force com­pa­nies to com­ply, oth­er than by main­tain­ing an an­nu­al list of drugs that have vi­o­lat­ed the rule.

“We an­tic­i­pate that the pri­ma­ry en­force­ment mech­a­nism will be the threat of pri­vate ac­tions un­der the Lan­ham Act sec. 43(a), 15 U.S.C. 1125(a), for un­fair com­pe­ti­tion in the form of false or mis­lead­ing ad­ver­tis­ing,” the CMS added.

Rachel Sachs

But Rachel Sachs, as­sis­tant pro­fes­sor of law at Wash­ing­ton Uni­ver­si­ty in St. Louis, ex­plained to Fo­cus that it’s not clear that all com­pa­nies would even have com­peti­tors to file such suits un­der the Lan­ham Act, or that com­peti­tors would even file such suits be­cause of how ex­pen­sive they are.

Sachs al­so ex­plained how she does be­lieve an en­ti­ty will sue the CMS on Con­sti­tu­tion­al and statu­to­ry grounds be­fore this fi­nal rule is im­ple­ment­ed. She said the CMS will like­ly be chal­lenged be­cause of the broad in­ter­pre­ta­tion of its au­thor­i­ty to reg­u­late drug ad­ver­tis­ing.

“More gen­er­al­ly, we should be skep­ti­cal that trans­paren­cy on its own can en­cour­age phar­ma­ceu­ti­cal com­pa­nies to low­er prices,” Sachs added. “It doesn’t mean it’s bad pol­i­cy, but it’s im­por­tant to make sure the ad­min­is­tra­tion is do­ing oth­er re­forms along­side” this one.

Fi­nal Rule


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval.

The PD-L1 drug is now sanctioned as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma, applicable in cases where cancer hasn’t progressed after platinum-containing chemotherapy.

Petros Grivas, the principal investigator of the supporting Phase III JAVELIN Bladder 100, called the approval “one of the most significant advances in the treatment paradigm in this setting in 30 years.”

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Merck has notched an approval for using Keytruda to treat a biomarker-based subset of first-line colorectal cancer patients with unresectable or metastatic tumors, as the pharma giant continues to find new niches for its blockbuster PD-1 star.

The OK is significant in a number of ways. Not only does it build on an accelerated approval for all tumors characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); it also marks the first single treatment for colorectal cancer that doesn’t contain chemotherapy.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

Sanofi is reportedly once again sharpening up the budget axe as the pharma giant prepares to chop more jobs.

Reuters reports this morning that Sanofi has its sights set on cutting 1,680 jobs in Europe, where the unions have been combating rounds of cutbacks at the Paris-based player. Sanofi itself hasn’t said anything about these cuts, as the company looks to discuss a 3-year plan with staff representatives.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Randy Schatzman, Bolt CEO (Bolt Biotherapeutics)

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

A cancer-fighting concept from the inventor of the first cancer vaccine is nearing prime time, and its biotech developer has received a significant new infusion of cash to get it there.

Bolt Biotherapeutics announced a $93.5 million Series C round led by Sofinnova Investments and joined by more than 9 others, including Pfizer Ventures and RA Capital Management. That money will go toward pushing the San Francisco biotech’s platform of innate immune-boosting warheads through its first trial on metastatic solid tumors and into several more.